Christian Heidbreder
Known title: Chief Scientific OfficerCIK: 0002014639
Associated companies
Transaction History
| INDV | ▼ Sell | Open Market | 18,586 | $765K | 7/10/2026 | View on chart |
| INDV | ▼ Sell | Open Market | 18,586 | $707K | 6/11/2026 | View on chart |
| INDV | ▲ Buy | Option Exercise | 101,544 | — | 3/3/2026 | View on chart |
| INDV | ▼ Sell | Tax Withholding | 45,797 | $1.5M | 3/3/2026 | View on chart |
| INDV | ▲ Buy | Grant | 33,622 | $0 | 2/10/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Indivior reports Sublocade sales growth and higher profitability
Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.
Indivior reports Sublocade sales growth and higher profitability. Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.